---
category: news
title: "The CEO of a $1.6 billion biotech says his bet on AI is paying off with faster, cheaper research that could reshape the industry"
excerpt: "Recursion says it can get drugs to the start of human testing at only 20% of the average cost while vetting potential treatments twice as fast."
publishedDateTime: 2023-01-25T14:30:00Z
originalUrl: "https://www.businessinsider.com/recursion-pharmaceuticals-ceo-interview-ai-in-biotech-2023-outlook-2023-1"
webUrl: "https://www.businessinsider.com/recursion-pharmaceuticals-ceo-interview-ai-in-biotech-2023-outlook-2023-1"
type: article
quality: 38
heat: 38
published: false

provider:
  name: Business Insider
  domain: businessinsider.com
  images:
    - url: "https://everyday-cc.github.io/ai/assets/images/organizations/businessinsider.com-50x50.jpg"
      width: 50
      height: 50

topics:
  - AI

images:
  - url: "https://i.insider.com/63d05e2940fbb600192b50cc?width=1200&format=jpeg"
    width: 1200
    height: 600
    isCached: true

secured: "yHnBy1xPN1BFLqxficqKP5rlh1wjmGzi18jrGKb8ttHFOHavM3yhgNmZpsoCp3kQ35ZUfnBF3XJoJ1vB3qyM5yUDZ3k4KUNp/987kd7NQ6II3738O3mNdY1p1xjuH9QzO4rqyhvB+Jy3bB3aB+0xnYC60rMDp1+Y/qbXDMvlMlsXrWywiVcdVpJ3HUav2/x6a7qTqT1H0Y6pj/VlT+G6dpZvXy6BIkHw/+0EO3iKW8szDfae7jbwr2gQ2KwCH9sFA9HQs9FzCiGXS48jm/AW4sf4rF9CezCdtlVk6ea+kp6c0TYu9sOrzJsp9pA2Q0XKIdRLF0f/fC7Qf1K1i0TSZ1S9hbPFzpcxHr4q+w+ROGE=;6o1ig9LjglndVpidQswWxw=="
---

